The Ensign Group (ENSG)
(Delayed Data from NSDQ)
$148.43 USD
-0.61 (-0.41%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $148.38 -0.05 (-0.03%) 7:58 PM ET
3-Hold of 5 3
C Value C Growth C Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$148.43 USD
-0.61 (-0.41%)
Updated Oct 18, 2024 04:00 PM ET
After-Market: $148.38 -0.05 (-0.03%) 7:58 PM ET
3-Hold of 5 3
C Value C Growth C Momentum B VGM
Zacks News
HCA Healthcare (HCA) Drives Efficiency With New Outpatient Model
by Zacks Equity Research
HCA Healthcare's (HCA) Sarah Cannon Cancer Institute adopts a new outpatient model for CAR T-cell therapy patients.
Teladoc Health (TDOC) Q4 Loss Narrows on Lower Expenses
by Zacks Equity Research
Teladoc Health's (TDOC) Q4 results were aided by strong contributions from the Integrated Care unit and a decline in restructuring costs. Management targets adjusted EBITDA at a minimum of $425 million in 2025.
The Ensign Group, Inc. (ENSG) Hit a 52 Week High, Can the Run Continue?
by Zacks Equity Research
Ensign Group (ENSG) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Here's Why Ensign Group (ENSG) is a Strong Value Stock
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Encompass Health (EHC) Q4 Earnings Beat on Higher Discharges
by Zacks Equity Research
Encompass Health's (EHC) Q4 results gain on improved net patient revenue per discharge and higher net income. Management estimates 2024 adjusted EPS to be $3.77-$4.06.
Ensign Group (ENSG) Q4 Earnings Beat, Stock Up 5%
by Zacks Equity Research
Ensign Group's (ENSG) fourth-quarter results were aided by improved same-store occupancy and an increase in rental revenues. Management expects 2024 adjusted EPS within $5.29-$5.47.
Ensign Group (ENSG) Q4 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Ensign Group (ENSG) delivered earnings and revenue surprises of 0.79% and 0.54%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Should You Invest in the Invesco S&P SmallCap Health Care ETF (PSCH)?
by Zacks Equity Research
Sector ETF report for PSCH
Here's Why Ensign Group (ENSG) is a Strong Growth Stock
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Here's Why You Should Retain Humana (HUM) in Your Portfolio
by Zacks Equity Research
Humana (HUM) remains well-poised for growth, attributable to an aging U.S. population, contract wins, acquisitions and expanding cash reserves.
Ensign (ENSG) Buys 2 Nursing Facilities in Tennessee & Nevada
by Zacks Equity Research
The acquisition deals have increased Ensign's (ENSG) portfolio to encompass 299 healthcare operations spanning 14 states.
Ensign Group (ENSG) Rises 23% in 3 Months: More Room to Run?
by Zacks Equity Research
Ensign Group (ENSG) remains well-poised for growth, courtesy of an extensive treatment network, higher rental revenues and uninterrupted dividend hikes.
Ensign Group (ENSG) Sanctions 4% Quarterly Dividend Hike
by Zacks Equity Research
Ensign Group (ENSG) announces a dividend hike, underlining a strong financial position and continued focus on deploying capital to shareholders.
Why This 1 Momentum Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Why Ensign Group (ENSG) is a Top Growth Stock for the Long-Term
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Why Is Ensign Group (ENSG) Up 13.8% Since Last Earnings Report?
by Zacks Equity Research
Ensign Group (ENSG) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Should You Invest in the Invesco S&P SmallCap Health Care ETF (PSCH)?
by Zacks Equity Research
Sector ETF report for PSCH
Are You a Growth Investor? This 1 Stock Could Be the Perfect Pick
by Zacks Equity Research
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Henry Schein (HSIC) Q3 Revenues Miss, 2023 Guidance Cut
by Zacks Equity Research
Henry Schein's (HSIC) third-quarter 2023 performance demonstrates remarkable sales growth in the Technology and Value-Added Service businesses.
National Vision (EYE) Q3 Earnings Top Estimates, Margins Fall
by Zacks Equity Research
National Vision's (EYE) higher SG&A expenses in the third quarter reflect increases in performance-based incentives and stock-based compensations.
Illumina (ILMN) Q3 Earnings Surpass Estimates, '23 View Cut
by Zacks Equity Research
Illumina (ILMN) reports solid earnings in the third quarter of 2023 amid a challenging macro environment.
Phibro (PAHC) Q1 Earnings and Revenues Miss, Margins Down
by Zacks Equity Research
Phibro's (PAHC) fiscal 2024 first-quarter performance reflects reduced sales in Mineral Nutrition and Performance Products.
STERIS (STE) Q2 Revenues Surpass Estimates, Margins Down
by Zacks Equity Research
STERIS' (STE) fiscal 2024 second-quarter results reflect continued momentum in the Healthcare business.